Blair William & CO Guardant Health, Inc. Transaction History

Blair William & CO

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$28.82 - $77.35 $22,047 - $59,172	765 Added 9.15%	9,129 $368,000
Q1 2022 May 13, 2022	SELL	$48.25 - $100.49 $178,814 - $372,415	-3,706 Reduced 30.7%	8,364 $554,000
Q4 2021 Feb 14, 2022	SELL	$88.71 - $120.43 $1,508 - $2,047	-17 Reduced 0.14%	12,070 $1.21 Million
Q3 2021 Nov 12, 2021	SELL	$98.77 - $132.17 $546,099 - $730,767	-5,529 Reduced 31.39%	12,087 $1.51 Million
Q2 2021 Aug 12, 2021	SELL	$109.77 - $165.68 $21,185 - $31,976	-193 Reduced 1.08%	17,616 $2.19 Million
Q1 2021 May 13, 2021	BUY	$127.04 - $179.1 $364,477 - $513,837	2,869 Added 19.2%	17,809 $2.72 Million
Q4 2020 Feb 09, 2021	SELL	$99.96 - $135.93 $1.08 Million - $1.46 Million	-10,773 Reduced 41.9%	14,940 $1.93 Million
Q3 2020 Nov 06, 2020	BUY	$80.32 - $111.8 $513,887 - $715,296	6,398 Added 33.12%	25,713 $2.87 Million
Q2 2020 Aug 12, 2020	SELL	$60.49 - $97.5 $12,763 - $20,572	-211 Reduced 1.08%	19,315 $1.57 Million
Q1 2020 May 11, 2020	BUY	$59.04 - $88.81 $98,596 - $148,312	1,670 Added 9.35%	19,526 $1.36 Million
Q4 2019 Feb 13, 2020	SELL	$59.49 - $82.78 $163,240 - $227,148	-2,744 Reduced 13.32%	17,856 $1.4 Million
Q3 2019 Nov 12, 2019	BUY	$62.59 - $110.3 $60,837 - $107,211	972 Added 4.95%	20,600 $1.32 Million
Q2 2019 Aug 13, 2019	SELL	$63.94 - $91.11 $118,289 - $168,553	-1,850 Reduced 8.61%	19,628 $1.69 Million
Q1 2019 May 14, 2019	BUY	$34.3 - $97.98 $72,990 - $208,501	2,128 Added 11.0%	21,478 $1.65 Million
Q4 2018 Feb 14, 2019	BUY	$29.2 - $46.1 $565,020 - $892,035	19,350 New	19,350 $727,000

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $4.8B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.